Some medication dosages are calculated based on your body weight. This helps ensure you get the correct amount of medicine for your body size and health condition.
PIH works to make lifesaving medications accessible. We often see people suffering from diseases such as multidrug-resistant tuberculosis and AIDS, unable to access treatment because the medicines aren’t available.
Some medication dosages are calculated based on your body weight. This helps ensure you get the correct amount of medicine for your body size and health condition.
PIH works to make lifesaving medications accessible. We often see people suffering from diseases such as multidrug-resistant tuberculosis and AIDS, unable to access treatment because the medicines aren’t available.
Pomalidomide wholesaler, known by the brand name Pomalyst, is a drug used in the treatment of multiple myeloma. It works by preventing the growth of cancer cells and by blocking signals that control cell division. It can be used alone or in combination with other drugs. Pomalyst is available in capsule form and should be taken as directed by your doctor. This medication is a thalidomide derivative, and as such it can cause serious side effects. Patients should monitor themselves for any signs of a severe reaction, including a severe headache or stomach pain.
Despite recent advances in front-line multiple myeloma therapies, patients with relapsed or refractory disease have poor survival. Immunomodulatory agents, such as thalidomide and lenalidomide, have improved outcomes in this group of patients. However, their effectiveness diminishes with relapse or resistance to frontline therapy. Therefore, researchers have developed second-line therapies that combine these agents with other drugs to improve survival.
Celgene Corporation’s pomalidomide is one such agent. In a recently published phase III trial, pomalidomide combined with low-dose dexamethasone doubled median progression-free survival (PFS) compared to high-dose dexamethasone alone. The study included a broad population of heavily pretreated relapsed or refractory multiple myeloma patients who had exhausted other novel treatments. Among these, the study found that a higher age at diagnosis and fewer previous lines of therapy were predictors of better survival on pomalidomide. However, these factors did not reach statistical significance.
Patients in the MM003 trial received either pomalidomide at 2 mg daily with dexamethasone 40 mg weekly for 28 day cycles or 4 mg daily with dexamethasone for the same duration. In both groups, the response rate was similar: 46% achieved at least a partial response. Interestingly, both the 2 and 4 mg doses were well tolerated.
The pomalidomide manufacturer group experienced a higher frequency of grade 3 or greater hematologic toxicities, notably neutropenia (42% vs 15%) and thrombocytopenia (21% vs 24%) compared to the dexamethasone-only arm. However, these side effects were manageable with the addition of dexamethasone.
A lower incidence of atypical myelodysplastic syndrome was observed in both arms. The pomalidomide group also showed superior progression-free survival to the high-dose dexamethasone arm in the cytogenetic analysis subgroup, although this difference did not reach statistical significance.
Because of the potential for teratogenesis, women who are able to become pregnant should not take pomalidomide. Men should use contraception during treatment and for four weeks after it ends. If they plan to have children in the future, men should consider sperm banking before starting treatment. Women should not breastfeed while taking this medicine. This drug is present in semen, so it can be passed to unborn babies through breastfeeding. To decrease the risk of pregnancy, all men and women should use two forms of birth control during treatment and for four weeks after it ends.
Lamivudine is an antiviral medication that prevents the growth of HIV and Hepatitis B virus (HBV) in people with an active infection. This drug works by blocking the action of enzymes in the liver and in the blood that help the virus grow. It also slows the spread of the virus to new cells in the body.
This drug comes in tablet and oral solution forms. It is taken once or twice a day with food. This medicine has been shown to be safe in pregnancy, but tell your doctor if you are pregnant or plan to become pregnant. It is recommended that you use an effective barrier method of birth control while taking this medication.
Some of the side effects that may occur while taking lamivudine include diarrhea, nausea, stomach pains, headache, tiredness, loss of appetite and joint or muscle aches. It can also cause changes in your immune system that make it easier for other infections to take hold in your body. These changes are called Immune Reconstitution Syndrome and can be mild or severe.
In rare cases, lamivudine manufacturer can lead to a buildup of lactic acid in the blood, which is a life-threatening condition. It can also cause a fatty liver. People who are at a higher risk for these conditions include those who have had hepatitis B or hepatitis C; those who have had previous liver disease; and females of larger body size.
Pancreatitis, or swelling of the pancreas, has occurred rarely in people who take this medication. This can be serious and requires medical attention right away. Symptoms of pancreatitis include stomach bloating, pain, and tenderness when touched. If you have diabetes, each 15 mL dose of the oral solution contains 3 grams of sucrose. This medication has been shown to increase the levels of other sugars in the blood, especially sorbitol, and can cause complications.
The Centers for Disease Control recommends that women who are HIV-positive not breastfeed. This medication can pass through the mother's milk and may harm the baby. Children and those who cannot swallow tablets may be given the lamivudine oral solution, which is based on their weight. The doctor will determine the dosage.
Rifaximin is an antibiotic and works by inhibiting bacterial ribonucleic acid synthesis. It is also known to promote the growth of good bacteria in the gastrointestinal tract. The drug has been used for over a decade and is effective in a variety of conditions including travelers diarrhea, C difficile infection, and inflammatory bowel disease. It also has a positive impact on hepatic encephalopathy.
Hepatic encephalopathy (HE) is a condition that can occur in patients with liver cirrhosis. It causes symptoms such as slurred speech, memory problems, confusion, and trouble walking or standing. HE can also cause hallucinations, seizures, and loss of coordination. It is estimated that up to 30% of people with hepatitis C virus cirrhosis develop HE. The disease is a significant burden on patients and families. Fortunately, there are several treatment options available for this condition, including hepatitis C medications and nutritional supplements.
Researchers have found that rifaximin, a medication used to treat bacterial overgrowth in the gut, can prevent hepatic encephalopathy in patients with liver cirrhosis. The team of researchers from the University of Pittsburgh School of Medicine and Michigan Medicine has recently published their results in the Journal of Hepatology. The study included 136 patients who were randomized to receive either rifaximin or placebo for 18 months. The participants were grouped according to their Metavir fibrosis score from initial liver biopsies. The participants were blinded to the treatment assigned. Placebo tablets were identical in size and shape to rifaximin and were stored in sealed, opaque envelopes with randomization codes. Only authorized pharmacy personnel knew the codes.
The drug has been FDA-approved for the prevention of travelers diarrhea since 2004. A series of pivotal randomized trials have shown its effectiveness in reducing the duration of illness and number of stools after a trip abroad. In addition, Manufacturer of rifaximin has been shown to be efficacious in the management of complications of hepatic cirrhosis, such as hepatorenal syndrome and spontaneous bacterial peritonitis.
Studies show that the etiology of IBS-D is complex and involves changes in microbial, neurogenic, and psychogenic factors. However, there is evidence that an abnormal host immune response to the intestinal microbiome may play a role in the development of IBS-D. Several antimicrobials, such as metronidazole and ciprofloxacin, are often prescribed for this condition, but side effects of long-term use of these drugs such as peripheral neuropathy in the case of metronidazole and tendinitis or tenosynovitis in the case of ciprofloxacin limit their use.
In a recent animal model, Xu et al showed that rifaximin significantly reduced visceral hyperalgesia. In addition, he found that rifaximin altered the community composition of gut bacteria at both the phylum and family level, resulting in an increased relative abundance of Lactobacillus. This effect was mediated by a reduction in the expression of the proinflammatory transcription factor NF-kappa B.